That includes the recent decision to reject NHS use of AZ and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for HER2-low ...

There was a standoff between USAID and Elon Musk's Department of Government Efficiency (DOGE) over access to restricted areas ...

Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...

In a shock move, AstraZeneca has ditched a plan to invest £450 million ($558 million) in a new vaccine manufacturing plant in ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

It is incumbent not only on people to have the willingness to learn, but also on pharmaceutical and scientific industries to ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Robert F Kennedy Jr's first confirmation hearing was a fractious affair, marked by tough questions about his prior ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

The industry is grappling with significant market shifts amidst emerging technologies and changing demands. Companies are now ...